U.S., Nov. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07909889) titled 'Semaglutide for Weight Management During Hormone Therapy for Early Breast Cancer' on Oct. 27.
Brief Summary: This study will assess whether women with obesity and early estrogen receptor-positive breast cancer can complete 26 weeks of semaglutide treatment while continuing their prescribed hormone therapy for breast cancer. The researchers expect that semaglutide can be given alongside hormone therapy with good treatment adherence. The study will also examine side effects, weight changes, body composition, metabolic health and quality of life.
Thirty-two women will be randomly assigned to start semaglutide immediately or after a 26-...